Liquidia (LQDA) to Release Quarterly Earnings on Monday

Liquidia (NASDAQ:LQDA) will be issuing its quarterly earnings data before the market opens on Monday, November 11th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $3.66 million for the quarter, compared to analyst estimates of $7.92 million. Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. On average, analysts expect Liquidia to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Liquidia Trading Down 1.1 %

LQDA traded down $0.11 on Tuesday, hitting $10.35. 626,034 shares of the company’s stock were exchanged, compared to its average volume of 984,083. The firm has a market cap of $794.78 million, a PE ratio of -6.57 and a beta of 0.21. Liquidia has a twelve month low of $6.06 and a twelve month high of $16.99. The stock has a fifty day moving average of $10.31 and a two-hundred day moving average of $11.61.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on LQDA shares. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price objective on shares of Liquidia in a research note on Monday, August 19th. Bank of America decreased their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Scotiabank began coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. Finally, Lifesci Capital began coverage on shares of Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.67.

Insider Activity

In related news, insider Rajeev Saggar sold 2,260 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares in the company, valued at approximately $2,304,025.13. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Rajeev Saggar sold 2,260 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares in the company, valued at approximately $2,304,025.13. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Caligan Partners Lp bought 150,000 shares of Liquidia stock in a transaction that occurred on Friday, August 30th. The shares were acquired at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the acquisition, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 21,551 shares of company stock worth $236,021 over the last three months. Corporate insiders own 30.10% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).